Earnings
Viking CEO Eyes Outside Obesity Deals After $575 Million Raise, Favors Own Pipeline
CEO Brian Lian says Viking is aware of attractive external assets, though the company would rather keep its focus in-house.
VKTX
Viking Therapeutics (VKTX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Viking Wants A Maintenance Dosing Label For VK2735, But Says The Filing Plan Is 'TBD'
CEO Brian Lian said every-other-week and monthly dosing data would more likely come as a later supplement to the first FDA application.
SEC Filings
Viking Therapeutics Loss Doubles To $183 Million As Obesity Drug Trials Multiply
The obesity drug developer holds $960 million in cash after a September financing, as late-stage trial costs climb.